Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Simone Belmonti,Barbara Rossetti,Sara Modica,L. Paglicci,Alberto Borghetti,Arturo Ciccullo,Chiara Picarelli,Roberto Cauda,Andrea De Luca,Francesca Montagnani,Francesca Lombardi

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

2019

Simone Belmonti
Barbara Rossetti
Sara Modica
L. Paglicci
Alberto Borghetti
Arturo Ciccullo
Chiara Picarelli
Roberto Cauda
Andrea De Luca
Francesca Montagnani
Francesca Lombardi

Introduction Long-term comparative immunologic response to 13-valent pneumococcal conjugate vaccine (PCV13) versus 23-valent polysaccharide vaccine (PPV23) among HIV-infected adults has not yet been investigated.

Keywords:

Intensive care medicine
Pneumococcal vaccination
Virology
Polysaccharide Vaccine
Serology
Pneumococcal conjugate vaccine
Medicine
Streptococcus pneumoniae
Immunology
Vaccination
hiv infected
Immunogenicity
Serotype
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations